XML 26 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Equity - USD ($)
Total
Common stock
Accumulated deficit
Non-controlling interest
Beginning balance (in shares) at Dec. 31, 2021   14,742,754    
Beginning balance at Dec. 31, 2021 $ 42,601,978 $ 48,452,906 $ (5,638,600) $ (212,328)
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Net loss (5,650,039)   (5,570,241) (79,798)
Return of common stock - Methotrexate (in shares)   (180,000)    
Return of common stock - Methotrexate (399,600) $ (399,600)    
Share-based compensation (in shares)   171,655    
Share-based compensation 447,503 $ 447,503    
Repurchase of common shares (in shares)   (367,793)    
Repurchase of common shares $ (1,025,836) $ (1,025,836)    
Ending balance (in shares) at Dec. 31, 2022 14,366,316 14,366,616    
Ending balance at Dec. 31, 2022 $ 35,974,006 $ 47,474,973 (11,208,841) (292,126)
Increase (Decrease) in Shareholders' Equity [Roll Forward]        
Net loss (6,330,766)   (6,279,320) (51,446)
Return of common stock - Methotrexate 0      
Share-based compensation (in shares)   157,360    
Share-based compensation 365,040 $ 365,040    
Repurchase of common shares (in shares)   (402,143)    
Repurchase of common shares $ (748,411) $ (748,411)    
Ending balance (in shares) at Dec. 31, 2023 14,121,833 14,121,833    
Ending balance at Dec. 31, 2023 $ 29,259,869 $ 47,091,602 $ (17,488,161) $ (343,572)